Pediatr. pro Praxi, 2005; 3: 142-146

MENINGOCOCCAL VACCINES

MUDr. Pavla Křížová CSc
Oddělení bakteriálních vzdušných nákaz, Centrum epidemiologie a mikrobiologie

Meningococcal vaccines provide specific immunity against the antigens (polysaccharide or proteine) included. A decrease of invasive meningococcal disease caused by Neisseria meningitidis C was observed in the Czech Republic in 2004/2005 and mass vaccination by conjugated MenC vaccine is not recommended in this epidemiological situation. NRL recommends vaccination by conjugated MenC vaccine of children before the age of 14 years. Conjugated vaccine is more suitable than polysaccharide vaccine because of building long-lasting persistence of protective level of immunity. The polysaccharide tetravaccine A+C+Y+W135, which is recommended for the vaccination of travellers and for achieving of the most broad immunity, is imported to the Czech Republic since 2005.

Keywords: Key words: meningococcal vaccine, invasive meningococcal disease, vaccination.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Křížová P. MENINGOCOCCAL VACCINES. Pediatr. praxi. 2005;6(3):142-146.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51: 717-722. Go to original source... Go to PubMed...
    2. Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-nave controls. Vaccine 2001; 19: 3043-3050. Go to original source... Go to PubMed...
    3. Borrow R, Goldblatt D, Andrews N, et al. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001; 184: 377-380. Go to original source... Go to PubMed...
    4. Burian V, Gotschlich EC, Kuzemenska P, Svandova E. Naturally occuring antibodies to Neisseria meningitidis. Bull WHO 1977; 55: 653-657. Go to PubMed...
    5. Finne JM, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development. Lancet 1983; ii: 355-357. Go to original source... Go to PubMed...
    6. Knaust A, Frosch M. Genome-based vaccines. Int J Med Microbiol 2004; 294: 295-301. Go to original source... Go to PubMed...
    7. Křížová P. Invazivní meningokokové onemocnění. Pediatrie pro praxi 2001; 2(2): 74-78.
    8. Kriz P, Vlckova J, Bobak M. Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic. Epidemiol Infect 1995; 15: 411-418. Go to original source... Go to PubMed...
    9. Kriz P, Kriz B, Svandova E, Musilek M. Antimeningococcal herd immunity in the Czech Republic - influence of an emerging clone, Neisseria meningitidis ET-15/37. Epidemiol Infect 1999; 123: 193-200. Go to original source... Go to PubMed...
    10. Kriz P. Surveillance of invasive meningococcal disease in the Czech Republic. Eurosurveillance Monthly 2004; 9: 11-12. Go to original source...
    11. Křížová P. Současné možnosti vakcinace proti meningokokům. Klinická mikrobiologie a infekční lékařství 2005; 11: 25-29. Go to PubMed...
    12. Křížová P, Kalmusová J, Musílek M. Invazivní meningokokové onemocnění v České republice v roce 2004. Zprávy CEM (SZÚ Praha) 2004; 14(3): 129-139.
    13. Lakshman R, Burkinshaw R, Choo S, Finn A. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults. Vaccine 2002; 20: 3778-3782. Go to original source... Go to PubMed...
    14. Maiden MC, Stuart JM, UK Meningococcal Carraige Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829-1831. Go to original source... Go to PubMed...
    15. Mora M, Veggi D, Santini L, Pizza M, Rappuoli R. Reverse vaccinology. Drug Discov Today 2003; 8: 459-464. Go to original source... Go to PubMed...
    16. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J. 2004; 23 (12 Suppl): S274-S279. Go to original source... Go to PubMed...
    17. Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis 1995; 4: 13-28. Go to PubMed...
    18. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181: 761-764. Go to original source... Go to PubMed...
    19. Southern J, Deane S, Ashton L, et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004; 11: 1100-1104. Go to original source... Go to PubMed...
    20. Zollinger WD. New and improved vaccines against meningococcal disease. In: New Generation Vaccines. Levine MM, Woodrow GC, Kaper JB, and Cobon GS, eds. Marcel Dekker, New York. 1997: 469.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.